Phase 3 Clinical Trials With Primary Completion Dates in February 2017
This is a list of Phase 3 trials with primary completion dates in February 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AERI | Aerie Pharmaceuticals, Inc. | 2017-02-01 | Phase 3 | NCT02674854 | Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension |
| ANTH | Anthera Pharmaceuticals, Inc. | 2017-02-01 | Phase 3 | NCT02279498 | SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis |
| CEMP | Cempra, Inc. | 2017-02-01 | Phase 3 | NCT02570490 | Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections |
| EARS | Auris Medical Holding AG | 2017-02-01 | Phase 3 | NCT01934010 | AM-101 in the Treatment of Post-Acute Tinnitus 1 |
| FGEN | FibroGen, Inc | 2017-02-01 | Phase 3 | NCT02174731 | Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis |
| IPXL | Impax Laboratories, Inc. | 2017-02-01 | Phase 3 | NCT02770365 | Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy |
| MYGN | Myriad Genetics, Inc. | 2017-02-01 | Phase 3 | NCT01844986 | Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. |
| NKTR | Nektar Therapeutics | 2017-02-01 | Phase 3 | NCT02362672 | Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain |
| REPH | Recro Pharma, Inc. | 2017-02-01 | Phase 3 | NCT02720692 | Evaluation of N1539 Following Major Surgery |
| TRVN | Trevena, Inc. | 2017-02-01 | Phase 3 | NCT02820324 | Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty |
| TRVN | Trevena, Inc. | 2017-02-01 | Phase 3 | NCT02815709 | Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy |
| TRVN | Trevena, Inc. | 2017-02-01 | Phase 3 | NCT02656875 | A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain |
| ZGNX | Zogenix, Inc. | 2017-02-01 | Phase 3 | NCT02682927 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome |